ubiquinone and Adrenal-Insufficiency

ubiquinone has been researched along with Adrenal-Insufficiency* in 2 studies

Other Studies

2 other study(ies) available for ubiquinone and Adrenal-Insufficiency

ArticleYear
Evaluation of antioxidant systems in pituitary-adrenal axis diseases.
    Pituitary, 2010, Volume: 13, Issue:2

    The role of adrenal steroids in antioxidant regulation is not known. Previously, we demonstrated some Coenzyme Q(10) (CoQ(10)) alterations in pituitary diseases, which can induce complex pictures due to alterations of different endocrine axes. Therefore we determined CoQ(10) and Total Antioxidant Capacity (TAC) in pituitary-dependent adrenal diseases: 6 subjects with ACTH-dependent adrenal hyperplasia (AH); 19 with secondary isolated hypoadrenalism (IH), 19 with associated hypothyroidism (multiple pituitary deficiencies, MPH). CoQ(10) was assayed by HPLC; TAC by the system metmyoglobin-H(2)O(2), which, interacting with the chromogenous 2,2(I)-azinobis-(3-ethylbenzothiazoline-6-sulphonate), generates a spectroscopically revealed radical compound after a latency time (Lag) proportional to the antioxidant content. CoQ(10) levels were significantly lower in IH than AH and MPH, with a similar trend when adjusted for cholesterol. Also TAC was lower in IH than in AH and MPH, suggesting that adrenal hormones can influence antioxidants. However, since thyroid hormones modulate CoQ(10) levels and metabolism, when thyroid deficiency coexists it seems to play a prevalent influence.

    Topics: Adrenal Hyperplasia, Congenital; Adrenal Insufficiency; Antioxidants; Chromatography, High Pressure Liquid; Humans; Hypothyroidism; Pituitary-Adrenal System; Ubiquinone

2010
Coenzyme Q10 evaluation in pituitary-adrenal axis disease: preliminary data.
    BioFactors (Oxford, England), 2005, Volume: 25, Issue:1-4

    In previous works we have demonstrated plasma CoQ10 alterations in pituitary diseases, such as acromegaly or secondary hypothyroidism. However, pituitary lesions can induce complex clinical pictures due to alterations of different endocrine axes controlled by pituitary itself. A further rationale for studying CoQ10 in pituitary-adrenal diseases is related to the common biosynthetic pathway of cholesterol and ubiquinone. We have therefore assayed plasma CoQ10 levels in different conditions with increased or defective activity of pituitary-adrenal axis (3 subjects with ACTH-dependent adrenal hyperplasia, 2 cases of Cushing's disease and 1 case of 17-alpha-hydroxylase deficiency; 10 subjects with secondary hypoadrenalism, including three subjects with also secondary hypothyroidism). CoQ10 levels were significantly lower in isolated hypoadrenalism than in patients with adrenal hyperplasia and multiple pituitary deficiencies (mean +/- SEM: 0.57 +/- 0.04 vs 1.08 +/- 0.08 and 1.10 +/- 0.11 microg/ml, respectively); when corrected for cholesterol levels, the same trend was observed, but did not reach statistical significance. These preliminary data indicate that secretion of adrenal hormones is in some way related to CoQ10 levels, both in augmented and reduced conditions. However, since thyroid hormones have an important role in modulating CoQ10 levels and metabolism, when coexistent, thyroid deficiency seems to play a prevalent role in comparison with adrenal deficiency.

    Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenal Insufficiency; Adult; Aged; Cholesterol; Coenzymes; Female; Humans; Hydrocortisone; Hyperplasia; Hypothyroidism; Male; Middle Aged; Pituitary Diseases; Pituitary-Adrenal System; Thyroxine; Triiodothyronine; Ubiquinone

2005